Key result
Serum fetuin-A levels >/mL indicated an acute phase of Takotsubo cardiomyopathy without cardiac decompensation, and levels >/mL predicted relevant rhythm disorders.
Why the study?
Valid markers for predicting outcomes in Takotsubo cardiomyopathy are unavailable, and novel cardiovascular risk biomarkers had not been evaluated for clinical implementation in these patients.
Do serum levels of fetuin-A and other novel biomarkers predict clinical complications in the acute phase of Takotsubo cardiomyopathy?
Observational (n=51)
Do serum levels of fetuin-A and other novel biomarkers predict clinical complications in the acute phase of Takotsubo cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Fetuin-A measured within 24 hours of admission may help risk-stratify patients with Takotsubo cardiomyopathy for acute complications like cardiac decompensation and arrhythmias.
Introduction: Takotsubo cardiomyopathy (TTC) remains a life-threatening disease with the risk of decompensated heart failure and arrhythmias. Valid markers for the prediction of outcome are unavailable. The novel biomarkers fetuin-A, matrix metalloproteinases-2 (MMP-2), myeloperoxidase (MPO), Syndecan-1 and CD40-L show promising results for risk stratification of cardiovascular patients. Nevertheless, clinical implementation has not been investigated in TTC patients. Methods: To investigate this issue, we evaluated clinical complications in 51 patients hospitalized for TTC and measured the serum levels of fetuin-A, MPO, MMP-2, Syndecan-1 and CD40-L within 24 h after admission. Results: Serum levels of Fetuin-A correlated inversely with the risk of cardiac decompensation and all cause complications within the acute phase of TTC. Fetuin-A levels over 190.1 µg/mL (AUC: 0.738, sensitivity 87.5%, specificity: 52.6%) indicate an acute phase of TTC without cardiac decompensation. Despite lower fetuin-A levels in patients with all cause complications, the combined endpoint remained slightly unmet (p = 0.058, AUC: 0.655). Patients with fetuin-A levels over 213.3 µg/mL are at risk of experiencing hemodynamic relevant rhythm disorders (AUC: 0.794; sensitivity: 75.0%, specificity: 79.1%). Other biomarkers failed to reveal a prognostic impact. Pro-BNP and hs troponin levels at admission did not predict adverse cardiac events. Conclusion: Fetuin-A is a promising marker in our study and could be of benefit for the prediction of short-term adverse cardiac events in TTC patients. Therefore, fetuin-A might be of value to evaluate an individual’s risk for complications within the acute phase of TTC and to individually choose the time of intensive care and hospitalization.
No takes yet. Share an insight, caveat, or question.
Topf et al. (2021) conducted an observational in Takotsubo cardiomyopathy (n=51). Fetuin-A was evaluated on Cardiac decompensation and all cause complications (AUC 0.655, p=0.058). Serum fetuin-A levels >/mL indicated an acute phase of Takotsubo cardiomyopathy without cardiac decompensation, and levels >/mL predicted relevant rhythm disorders.
Synapse has enriched 10 related papers. Consider them for comparative context: